Pyrazole compounds as btk inhibitors
US-2016340339-A1 · Nov 24, 2016 · US
Heteroaromatic compounds as BTK inhibitors
US10138229B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10138229-B2 |
| Application number | US-201715814927-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 16, 2017 |
| Priority date | Aug 10, 2012 |
| Publication date | Nov 27, 2018 |
| Grant date | Nov 27, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound chosen from: or a pharmaceutically acceptable salt thereof. 2. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 3. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 4. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 5. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 6. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 7. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 8. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 9. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 10. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 11. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 12. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 13. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 14. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 15. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 16. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 17. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 18. The compound according to claim 1 of formula: or a pharmaceutically acceptable salt thereof. 19. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof. 20. A method of treating a disease chosen from rheumatoid arthritis, systemic lupus erythromatosis, scleroderma, asthma, allergic rhinitis, allergic eczema, B cell lymphoma, multiple sclerosis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis, inflammatory bowel disease, graft versus host disease, psoriatic arthritis, ankylosing spondylitis and uveitis, comprising administering to a patient a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
specific for leukemia · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10138229B2 cover?
- The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
- Who is the assignee on this patent?
- Boehringer Ingelheim Int
- What technology area does this patent fall under?
- Primary CPC classification C07D401/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).